alexa Membranous nephropathy | United-states | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • Global Physicians and Healthcare Congress
    June 25-27, 2018 Dubai, UAE
  • International Conference on Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • 11th International Conference on Clinical and Medical Case Reports
    October 22-23, 2018 Istanbul, Turkey

Relevant Topics

Membranous Nephropathy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Membranous nephropathy

    Membranous nephropathy 
    is characterized by diffuse thickening of the glomerular capillary basement membrane by subepithelial immune complex deposition. This results in damage and increased permeability of the basement membrane to plasma proteins and hence nephrotic range proteinuria.

  • Membranous nephropathy

    Disease pathophysiology: 

    Autoantibodies to PLA2R1, usually of IgG4 subclass, are found in about 80% of patients with primary MN. These autoantibodies bind to genetically determined, conformational epitopes on PLA2R1, form immune complexes in situ and induce proteinuria, via the mannose-binding lectin pathway. The level of autoantibody to PLA2R correlates with the severity of the clinical disease.

  • Membranous nephropathy

    Disease statistics:

    In the US, the prevalence of membranous nephropathy is close to 2000 patients per year. In contrast to other primary glomerular diseases, the incidence of MN has remained constant since the 1980s. It is one of the most common causes of nephrotic syndrome globally, just behind focal segmental glomerular sclerosis, which is the most common aetiology. 

  • Membranous nephropathy

    Disease treatment:

    Immunotherapy to treat immune-mediated kidney disease including Membranous Nephropathy. It is a comprehensive treatment with the treating process of blocking the undue inflammatory response, clearing up the immune complex, protecting the healthy renal cells and tissues, recovering the impaired kidney function and regulating the immune system. 

  • Membranous nephropathy

    Major research on disease:

    MN, a rare kidney disease in which the immune system attacks a protein found in the kidneys, causing thickening of the small blood vessels in the kidney, proteinuria, and sometimes kidney failure. The scientists discovered the site where antibodiesbind to this protein, known as PLA2R, as well as the peptides, or small molecules, that could prevent binding. 

Expert PPTs

Speaker PPTs

  • Hayam I Gad
    Effects of Pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of Diabetic nephropathy in an experimental model of diabetic renal disease
    PPT Version | PDF Version

High Impact List of Articles

Conference Proceedings